Table 4 Small bowel carcinoma molecular alterations: distribution among clinical groups and survival analysis

From: Small bowel carcinomas in celiac or Crohn’s disease: distinctive histophenotypic, molecular and histogenetic patterns

 

Distribution among clinical groups

Total cases

Survival analysis

 

Celiac disease carcinomas

Crohn’s disease carcinomas

Sporadic carcinomas

 

Hazard ratio (95% confidence interval)

P-value

Nuclear β-catenin, C-terminal antibody

24/26 (92%)a

6/24 (25%)

10/25 (40%)

40/75 (53%)

0.30 (0.14–0.63)

0.002

Nuclear N-terminal β-catenin loss

10/26 (38%)

2/24 (8%)

5/25 (20%)

17/75 (23%)

0.49 (0.22–1.12)b

0.091

 Among C-terminal β –catenin-positive cases

10/24 (42%)

2/6 (33%)

5/10 (50%)

17/40 (42%)

0.85 (0.24–2.97)c

0.796

SOX-9 expression

20/23 (87%)

11/22 (50%)

14/23(51%)

45/68 (66%)

0.70 (0.31–1.56)

0.380

Microsatellite instability d

17/26 (65%)e

4/25 (16%)

4/25 (16%)

25/76 (33%)

0.22 (0.08–0.64)

0.005

 Among C-terminal β–catenin-positive cases

17/24 (71%)a

1/6 (17%)

2/10 (20%)

20/40 (50%)

0.14 (0.04–0.50)

0.002

  1. aP<0.001 vs Crohn’s disease-associated carcinomas or sporadic carcinomas.
  2. bVs remaining small bowel carcinomas.
  3. cVs remaining C-terminal β-catenin-positive cases.
  4. dAll 17 microsatellite unstable cases also had nuclear β-catenin among celiac disease-associated carcinomas; as against only one of the 4 among Crohn’s disease-associated carcinomas and 2 of the 4 among sporadic carcinomas.
  5. eP=0.001 vs Crohn’s disease-associated carcinomas or sporadic carcinomas.
Back to article page